Drug intelligence / Profile preview

ChAd63-PfCAT

Development stage: Phase 1
Lead developer: University of Oxford
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

ChAd63-PfCAT is a recombinant, non-replicating simian adenovirus serotype 63 (ChAd63) vectored vaccine candidate developed by the Jenner Institute at the University of Oxford for the prevention of malaria. The vaccine encodes a unique fusion protein, PfCAT, which consists of three highly conserved *Plasmodium falciparum* antigens: the circumsporozoite protein (CSP), apical membrane antigen 1 (AMA1), and thrombospondin-related anonymous protein (TRAP). This multi-antigen approach is designed to target the malaria parasite at both the pre-erythrocytic stage (via CSP and TRAP) and the blood stage (via AMA1). By utilizing a viral vector to deliver the genetic sequence for these antigens, the vaccine induces robust cellular (CD8+ and CD4+ T-cell) and humoral (antibody) immune responses. In clinical development, ChAd63-PfCAT is frequently evaluated in heterologous prime-boost regimens alongside a Modified Vaccinia Virus Ankara (MVA) vector encoding the same antigens (MVA-PfCAT) to enhance protective efficacy.

Other names: Simian adenovirus 63 encoding PfCATChAd63 PfCATChAd-63 PfCATChAd 63 PfCAT

Targets

AMA1 (Apical membrane antigen 1)TRAP (Thrombospondin-related anonymous protein)CSP (Circumsporozoite protein)

Beyond the preview

Go deeper on ChAd63-PfCAT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChAd63-PfCAT.

Explore the full profile